VIOXX WITHDRAWAL: FDA TO JOIN AUDIO CONFERENCE ON NOVEMBER 10 Mon, 8 Nov 2004 To hear from FDA Office of New Drugs Acting Director Sandra Kweder, MD, in an interactive discussion of what the withdrawal of the blockbuster drug means for the agencys drug safety programs, the COX-2 inhibitor class and the drug industry as…

Read More

Daniel Troy Legacy: Public Virtually Defenseless against Unsafe Drugs Thu, 18 Nov 2004 The Associated Press reports that at a Congressional hearing today, Dr. David Graham a drug safety expert at the FDA told the Senate Finance Committee that the public is “virtually defenseless” if another medication such as Vioxx proves unsafe after it has…

Read More

A Disease for Every Pill – FDA Hearing Drug Advertising Wed, 5 Oct 2005 The FDA has called for a public hearing to address direct to consumer drug advertising. Hearing Date: November 1 and 2, 2005 Hearing Name: Direct-To-Consumer Promotion Location: National Transportation Safety Board Boardroom and Conference Center 429 L’Enfant Plaza, SW., Washington, DC.…

Read More

The independent Institute of Science in Society (ISIS) challenges the report issued by the UK government medicines oversight agency, MHRA (equivalent to US FDA), absolving itself and those involved from any responsibility for a catastrophic human experiment that nearly killed six healthy volunteers.

Read More

“Lilly is Hiding Negative Information About Zyprexa” – SAPS Wed, 2 Nov 2005 From our colleague in Sweden: A published interview with Dr. Curt Furberg, Professor of Public Health Sciences Wake Forest University Baptist Medical Center, and Chair, Steering Committee, and Principal Investigator, of one of the most important studies ever on Antihypertensive and Lipid-Lowering…

Read More